期刊文献+

多西他赛联合FOLFOX4方案治疗晚期胃癌40例临床观察 被引量:3

下载PDF
导出
摘要 目的探讨多西他赛+FOLFOX4方案对晚期胃癌的疗效及毒副作用。方法晚期胃癌患者40例,给予以下化疗方案:多西他赛60 mg/m2静脉滴注,第1天;奥沙利铂85 mg/m2静脉滴注,第1天;亚叶酸钙(CF)200 mg/m2静脉滴注,第1、2天;5-氟尿嘧啶(5-Fu)400 mg/m2静脉推注,第1天,5-Fu 600 mg/m2持续静脉滴注46 h。14 d为1个周期,所有患者至少接受3个周期以上的化疗。结果 40例均可评价疗效,总有效率45.0%,中位生存时间9.3个月,中位肿瘤进展时间6.1个月。主要毒副反应为胃髓抑制、腹泻和脱发。结论多西他赛联合FOLFOX4方案治疗晚期胃癌的近期疗效好,毒副作用可以耐受。
作者 王海霞 王琳
机构地区 海南省人民医院
出处 《山东医药》 CAS 北大核心 2010年第24期57-58,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

二级参考文献41

  • 1[1]Sulkes A,Smyth J,Sessa C,et al.Docetaxel(Taxotere) in advanced gastric cancer:Results of a phase Ⅱ clinical trial.EORTC Early Clinical Trials Group.Br J Cancer,1994,70:380 被引量:1
  • 2[2]Einzig AI,Neuberg D,Remick SC,et al.Phase Ⅱ trial of docetaxel (Taxotere) in patients with adenoearcinoma of the upper gastrointestinal tract previously tmtreated with cytotoxic chemotherapy:The Eastern Cooperative Oncology Group(ECOG)resuits of protocol E1293.Med Oncol,1996,13:87 被引量:1
  • 3[3]Mavroudis D,Kourousis C,Androuiakis N,et al.Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor(G-CSF):A phase Ⅱ trial.Am J Clin Oncol,2000,23:341 被引量:1
  • 4[4]Bang YJ,Kang WK,Kang YK,et al.Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:A phase Ⅱ trial.Jpn J Clin Oncol,2002,32:248 被引量:1
  • 5[5]Taguchi T,Sakata Y,Kanamaru R,et al.Late phase Ⅱ clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer:A Japanese Cooperative Study Group Trial(group A).Gan To Kagaku Ryoho,1998,25:1915 被引量:1
  • 6[6]Vanhoefer U,Wilke H,Harstrick A,et al.Phase Ⅱ study of docetaxel as second-line chemotherapy in metastatic gastric cancer.Proc Am Soc Clin Oncol,1999,35th annual meeting:Abstract 1163 被引量:1
  • 7[7]Giuliani F,Gebbia V,De Vita F,et al.Docetaxel as salvage therapy in advanced gastric cancer:A phase Ⅱ study of the Gruppo Oncologico Italia Meridionale(G.O.I.M.).Anticancer Res,2003,23:4219 被引量:1
  • 8[8]Graziano F,Catalano V,Baldelli AM,et al.A phase Ⅱ study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer.Ann Oncol,2000,11:1263 被引量:1
  • 9[9]Burris HA.3rd.Docetaxel in combination with fluorouracil for advanced solid tumors.Oncology(Williston Park),1997.11:50 被引量:1
  • 10[10]Constenla M,Garcia-Arroyo R,Lorenzo I,et al.Docetaxel,5-fluorouracil,and leucovorin as treatment for advanced gastric cancer:Results of a phase Ⅱ study.Gastric Cancer,2002,5:142 被引量:1

共引文献91

同被引文献27

  • 1沈婕,何胜利,孙贤俊,朱晓娟,高勇.老年晚期胃癌患者卡培他滨节律化疗的临床疗效[J].肿瘤,2010,30(9):788-790. 被引量:18
  • 2秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 3IFultonB, SpencerCM, Docetaxel.A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer[J].Drugs, 1996, 51(6):1075-1092. 被引量:1
  • 4Crown J, O'Leary M.The taxanesl,an update [J].Lancet, 2000, 355(9210) : 1176. 被引量:1
  • 5Sulkes A, Smyth J, Sessac, et al.Docetaxel(Taxotere) in advanced gastric cancer:results of a phase II clinical trail[J].Br J cancer, 1994, 70(2):380-387. 被引量:1
  • 6Mavroudis D, Kourousis C, Androulakis N, et al.Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony- stimulating factor(G-CSF):A phase 11 trial[J].Am J Clin Oncol, 2000, 23(4):341-344. 被引量:1
  • 7] Bang Y J, Kang W K, Kang Y K, et al.Docetaxel 75 mg/m2 is active and well tolerated in patients with metaststic or recurrent gastic cancer:A phase II trial[J].JpnJ Clin Oncol, 2002, 32(7):248-254. 被引量:1
  • 8Zang D Y, Yang D H, Kin M J, et al.Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer[J].CancerChemotherpyPharmacol, 2009, 61(11):1545-1551. 被引量:1
  • 9Moehler M H, Thuss-Patience P, Arnold D, et al.Docetaxel, oxaliplatin, and Capecitabine(TEX regimen)for patients with metastatic gastric cancer:interim results from a phase II trim by the German AIO Group[J].J Clin Oncol(Meeting Abstracts), 2009, 27(1):45-54. 被引量:1
  • 10Shankaran V, Mulcahy M F, Hochster H S, et al.Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of Metastatic or unresectable gastric or gastroesophageal junction(GEJ) adeuocarcinomas:Preliminary results of a phase I1 study[J]. Gastrointestinal Cancers Synposinm, 2009, 23(1):47. 被引量:1

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部